Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Imprimis Pharmaceuticals (IMMY) Stock Price

News coverage about Imprimis Pharmaceuticals (NASDAQ:IMMY) has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.0105895935048 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Imprimis Pharmaceuticals (NASDAQ:IMMY) opened at $1.87 on Thursday. Imprimis Pharmaceuticals has a one year low of $1.35 and a one year high of $4.69. The company has a market capitalization of $38.40, a P/E ratio of -2.03 and a beta of -0.40. The company has a debt-to-equity ratio of 3.94, a quick ratio of 1.28 and a current ratio of 1.67.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter. Imprimis Pharmaceuticals had a negative net margin of 60.71% and a negative return on equity of 264.98%.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Imprimis Pharmaceuticals (IMMY) Stock Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/01/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-imprimis-pharmaceuticals-immy-stock-price.html.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply